Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 250

1.

A new Hu-PBL model for the study of human islet alloreactivity based on NOD-scid mice bearing a targeted mutation in the IL-2 receptor gamma chain gene.

King M, Pearson T, Shultz LD, Leif J, Bottino R, Trucco M, Atkinson MA, Wasserfall C, Herold KC, Woodland RT, Schmidt MR, Woda BA, Thompson MJ, Rossini AA, Greiner DL.

Clin Immunol. 2008 Mar;126(3):303-14. Epub 2007 Dec 21.

PMID:
18096436
2.

Rejection of human islets and human HLA-A2.1 transgenic mouse islets by alloreactive human lymphocytes in immunodeficient NOD-scid and NOD-Rag1(null)Prf1(null) mice.

Banuelos SJ, Shultz LD, Greiner DL, Burzenski LM, Gott B, Lyons BL, Rossini AA, Appel MC.

Clin Immunol. 2004 Sep;112(3):273-83.

PMID:
15308121
3.

Development of new-generation HU-PBMC-NOD/SCID mice to study human islet alloreactivity.

King M, Pearson T, Shultz LD, Leif J, Bottino R, Trucco M, Atkinson M, Wasserfall C, Herold K, Mordes JP, Rossini AA, Greiner DL.

Ann N Y Acad Sci. 2007 Apr;1103:90-3. Epub 2007 Mar 21.

PMID:
17376822
4.

Human lymphoid and myeloid cell development in NOD/LtSz-scid IL2R gamma null mice engrafted with mobilized human hemopoietic stem cells.

Shultz LD, Lyons BL, Burzenski LM, Gott B, Chen X, Chaleff S, Kotb M, Gillies SD, King M, Mangada J, Greiner DL, Handgretinger R.

J Immunol. 2005 May 15;174(10):6477-89.

5.

Alloimmune injury and rejection of human skin grafts on human peripheral blood lymphocyte-reconstituted non-obese diabetic severe combined immunodeficient beta2-microglobulin-null mice.

Turgeon NA, Banuelos SJ, Shultz LD, Lyons BL, Iwakoshi N, Greiner DL, Mordes JP, Rossini AA, Appel MC.

Exp Biol Med (Maywood). 2003 Oct;228(9):1096-104.

PMID:
14530522
6.

NOD/SCID/gamma(c)(null) mouse: an excellent recipient mouse model for engraftment of human cells.

Ito M, Hiramatsu H, Kobayashi K, Suzue K, Kawahata M, Hioki K, Ueyama Y, Koyanagi Y, Sugamura K, Tsuji K, Heike T, Nakahata T.

Blood. 2002 Nov 1;100(9):3175-82.

7.

Development of functional human blood and immune systems in NOD/SCID/IL2 receptor {gamma} chain(null) mice.

Ishikawa F, Yasukawa M, Lyons B, Yoshida S, Miyamoto T, Yoshimoto G, Watanabe T, Akashi K, Shultz LD, Harada M.

Blood. 2005 Sep 1;106(5):1565-73. Epub 2005 May 26.

8.

Development of novel major histocompatibility complex class I and class II-deficient NOD-SCID IL2R gamma chain knockout mice for modeling human xenogeneic graft-versus-host disease.

Pino S, Brehm MA, Covassin-Barberis L, King M, Gott B, Chase TH, Wagner J, Burzenski L, Foreman O, Greiner DL, Shultz LD.

Methods Mol Biol. 2010;602:105-17. doi: 10.1007/978-1-60761-058-8_7.

9.

Regulation of human cell engraftment and development of EBV-related lymphoproliferative disorders in Hu-PBL-scid mice.

Wagar EJ, Cromwell MA, Shultz LD, Woda BA, Sullivan JL, Hesselton RM, Greiner DL.

J Immunol. 2000 Jul 1;165(1):518-27.

11.

Human peripheral blood lymphocyte reconstituted severe combined immunodeficient (hu-PBL-SCID) mice. A model for human islet allograft rejection.

Shiroki R, Poindexter NJ, Woodle ES, Hussain MS, Mohanakumar T, Scharp DW.

Transplantation. 1994 Jun 15;57(11):1555-62.

PMID:
8009588
12.

Immunoglobulin-like transcript 3-Fc suppresses T-cell responses to allogeneic human islet transplants in hu-NOD/SCID mice.

Vlad G, D'Agati VD, Zhang QY, Liu Z, Ho EK, Mohanakumar T, Hardy MA, Cortesini R, Suciu-Foca N.

Diabetes. 2008 Jul;57(7):1878-86. doi: 10.2337/db08-0054. Epub 2008 Apr 16.

13.

Defucosylated anti-CCR4 monoclonal antibody exerts potent ADCC against primary ATLL cells mediated by autologous human immune cells in NOD/Shi-scid, IL-2R gamma(null) mice in vivo.

Ito A, Ishida T, Utsunomiya A, Sato F, Mori F, Yano H, Inagaki A, Suzuki S, Takino H, Ri M, Kusumoto S, Komatsu H, Iida S, Inagaki H, Ueda R.

J Immunol. 2009 Oct 1;183(7):4782-91. doi: 10.4049/jimmunol.0900699. Epub 2009 Sep 11.

14.

Non-obese diabetic-recombination activating gene-1 (NOD-Rag1 null) interleukin (IL)-2 receptor common gamma chain (IL2r gamma null) null mice: a radioresistant model for human lymphohaematopoietic engraftment.

Pearson T, Shultz LD, Miller D, King M, Laning J, Fodor W, Cuthbert A, Burzenski L, Gott B, Lyons B, Foreman O, Rossini AA, Greiner DL.

Clin Exp Immunol. 2008 Nov;154(2):270-84. doi: 10.1111/j.1365-2249.2008.03753.x. Epub 2008 Sep 8.

15.

Humanized NOD/LtSz-scid IL2 receptor common gamma chain knockout mice in diabetes research.

Shultz LD, Pearson T, King M, Giassi L, Carney L, Gott B, Lyons B, Rossini AA, Greiner DL.

Ann N Y Acad Sci. 2007 Apr;1103:77-89. Epub 2007 Mar 1.

PMID:
17332083
16.

Long-term engraftment and expansion of tumor-derived memory T cells following the implantation of non-disrupted pieces of human lung tumor into NOD-scid IL2Rgamma(null) mice.

Simpson-Abelson MR, Sonnenberg GF, Takita H, Yokota SJ, Conway TF Jr, Kelleher RJ Jr, Shultz LD, Barcos M, Bankert RB.

J Immunol. 2008 May 15;180(10):7009-18.

17.

Regulation of human short-term repopulating cell (STRC) engraftment in NOD/SCID mice by host CD122+ cells.

Shultz LD, Banuelos SJ, Leif J, Appel MC, Cunningham M, Ballen K, Burzenski L, Greiner DL.

Exp Hematol. 2003 Jun;31(6):551-8.

PMID:
12829032
18.

A humanized mouse model to study human immune response in xenotransplantation.

Ji M, Jin X, Phillips P, Yi S.

Hepatobiliary Pancreat Dis Int. 2012 Oct;11(5):494-8.

PMID:
23060394
19.

Hematopoietic stem cell-engrafted NOD/SCID/IL2Rgamma null mice develop human lymphoid systems and induce long-lasting HIV-1 infection with specific humoral immune responses.

Watanabe S, Terashima K, Ohta S, Horibata S, Yajima M, Shiozawa Y, Dewan MZ, Yu Z, Ito M, Morio T, Shimizu N, Honda M, Yamamoto N.

Blood. 2007 Jan 1;109(1):212-8. Epub 2006 Sep 5.

20.

The allogeneic response to cultured human skin equivalent in the hu-PBL-SCID mouse model of skin rejection.

Briscoe DM, Dharnidharka VR, Isaacs C, Downing G, Prosky S, Shaw P, Parenteau NL, Hardin-Young J.

Transplantation. 1999 Jun 27;67(12):1590-9.

PMID:
10401767

Supplemental Content

Support Center